{"nct_id":"NCT05260437","title":"Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants","status":"COMPLETED","status_verified_date":"2024-03","start_date":"2022-03-24","start_date_type":"ACTUAL","primary_completion_date":"2023-03-07","primary_completion_date_type":"ACTUAL","completion_date":"2023-03-07","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["GSK"]}